drugset / Trial / NCT06793371
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
Timeline
- Start
- 2025-02-06
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CK-4021586 | Unknown | 150 mg | Oral |
| Subject | CK-4021586 | Unknown | 300 mg | Oral |
| Subject | CK-4021586 | Unknown | 450 mg | Oral |
| Subject | CK-4021586 | Unknown | 600 mg | Oral |